Researchers have discovered a virus that could enter human cells in a similar way to COVID-19. But they caution it's much ...

The following is a summary of “Effectiveness and safety of anti-CGRP monoclonal antibodies for migraine in patients over 65 ...

The people were followed for 2.9 years on average. The CDR is used globally to determine if a person has a form of dementia. The scale includes six domains; three are cognitive and three are ...

VUMC received up to $30M to develop AI for antibody therapy discovery, aiming to create an antibody-antigen atlas and ...

The global bispecific antibody (BsAb) market has witnessed significant growth, with 17 bispecific antibody therapies already ...

Monoclonal antibodies like etesevimab have lost efficacy against Omicron subvariants, necessitating innovative solutions.

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

The first anti-amyloid monoclonal antibody -- and the first drug of any kind aimed at the Alzheimer's disease process -- gained FDA approval in June 2021: aducanumab (Aduhelm). However ...

VUMC has been awarded up to $30 million from the Advanced Research Projects Agency for Health (ARPA-H) to build a massive ...

Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

Therapeutic antibodies are used to treat a wide range of diseases ... antigen target is and have a good chance of generating a monoclonal antibody therapeutic against that target in a very ...

HONG KONG, China I March 16, 2025 I Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been ...